Jefferies Downgrades Metabolix to Hold

by Juan Lopez, Benzinga Staff Writer

January 13, 2012 6:12 AM | 8 seconds read | Make a Comment

Jefferies & Company has downgraded Metabolix

MBLX

from Buy to Hold and has lowered the price target from $9 to $4.

Posted In: Downgrades Price Target Pre-Market Outlook Analyst Ratings Biotechnology Health Care Jefferies & Company

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.